Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6691722 | 0.89 | HSP90AB1 (0.41) | HSP90AB1KMT2AMEN1CA12CA1 | |
| SCHEMBL6695182 | 0.82 | HSP90AB1 (0.61) | HSP90AB1DHODHKMT2AMEN1KDM4E | |
| SCHEMBL6698066 | 0.79 | HSP90AB1 (0.41) | HSP90AB1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL6696024 | 0.78 | MAPT (0.46) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL6696507 | 0.76 | RAD52 (0.51) | HSP90AB1DHODHKMT2AMEN1KDM4E | |
| SCHEMBL6696127 | 0.74 | MAPT (0.59) | HSP90AB1KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL6701729 | 0.74 | ADORA2A (0.57) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL6692442 | 0.73 | MAPT (0.49) | HSP90AB1DHODHKMT2AMEN1KDM4E | |
| SCHEMBL6690807 | 0.73 | GAA (0.41) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL6695082 | 0.72 | KDM4E (0.46) | HSP90AB1DHODHKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | claimed |
| EP-1274691-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GmbH (DE) | 2003-01-15 | — | — | EP | claimed |
| WO-2001079186-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GMBH (DE) | 2001-10-25 | — | — | WO | claimed |
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | MERCK PATENT GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| EP-1274691-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GmbH (DE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001079186-A1 | 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS | MERCK PATENT GMBH (DE) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224965-A1 | 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors | NHERF1, SLC9A3, SLC9A1 | HSP90AB1 1039/4885DHODH 3108/4885KMT2A 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.